[Disclosure] Celltrion Secures European CHMP Recommendation for Marketing Authorization of CT-P41 (068270)

Source Facts: Financial Supervisory Service Electronic Disclosure System (DART) / 2024-12-16

Disclosure Type: Major Management Matters Related to Investment Decisions

💡 3-Second Summary

Celltrion’s CT-P41 (denosumab), a biosimilar to Prolia and Xgeva, has obtained a positive opinion recommending marketing authorization for 30 European countries from the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA), pending the final official approval from the European Commission (EC).

📊 1. [Key Disclosure Content & Major Financial Figures Summary]

• Target Product: CT-P41 (Active ingredient: Denosumab), biosimilar to Prolia & Xgeva
• Target Diseases (Approved Indications in the Disclosure):
  • Prolia Indications:
    • Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures
    • Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures
    • Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of vertebral fractures
  • Xgeva Indications:
    • Prevention of skeletal related events in adults with advanced malignancies involving bone
    • Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity
• Key Schedule (Local Time):
  • Application Date: March 8, 2024
  • Date of CHMP Recommendation: December 12, 2024
  • Fact Confirmation Date: December 13, 2024 (Date confirmed via notifications from CHMP under EMA)
• Scope of Recommendation: Approval recommended for marketing across 30 European countries.
• Expectations & Plans:
  • The recommendation was obtained for all indications approved for the original products, which is expected to provide treatment options to patients.
  • Following this CHMP recommendation, Celltrion expects to secure final marketing authorization from the European Commission (EC) in the near future.

📈 2. [Expert Perspective: What This Disclosure Means for Investors]

This filing represents an administrative regulatory milestone indicating that CT-P41 has cleared the scientific evaluation body (CHMP), which serves as a major step prior to final marketing in Europe. This milestone was reached approximately nine months after the initial regulatory filing on March 8, 2024.

However, investors must note that the current status is a “recommendation” rather than the “final marketing authorization” from the European Commission (EC). While the company states that it expects to obtain final approval in the near future, the exact timing and final decision remain subject to the EC’s administrative procedures. Furthermore, because this disclosure does not include any financial figures or immediate impact on earnings, investors should recognize this stage as a positive recommendation and monitor the subsequent final authorization process.

📝 Editor’s Comment (by K-STOCK Editor)

This CHMP recommendation serves as the direct administrative outcome of the “European Marketing Authorization Application” disclosed on March 8, 2024. The essential fact is that the positive opinion was granted for all indications held by the original products listed in the filing, including three indications of Prolia and two indications of Xgeva.

It is critical to distinguish this positive opinion from the final permission to market the drug. Legally, commercial sales can only commence after the European Commission (EC) conducts its review and issues the final formal Marketing Authorization. This disclosure does not contain concrete commercialization schedules, expected pricing, or projected sales figures.

Consequently, the key objective checkpoint for investors moving forward is the official publication of the “Final Marketing Authorization Approval” from the European Commission (EC). Verifying that this final administrative step is finalized without unexpected delays remains the necessary baseline for evaluating any future impact on corporate value.

📢 Disclaimer & Source Information

Source: This content has been structured and newly drafted based on official data submitted to the Financial Supervisory Service Electronic Disclosure System (DART).

Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest solely with the investor.

Inquiries: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.